Ramses - absolutely not! It is without doubt an exciting drug....

Ramses - absolutely not! It is without doubt an exciting drug. But we do not know yet whether it is effective in human brain injury, or effective enough to go to market. Studies to this point would suggest that it has probably a better chance than any previous drug in its class (neuroprotective agents) of conferring benefit in patients with brain injury, but all previous NNZ2256 studies have been in models (tissue, animal etc) and not in living humans. On average, a drug at this stage of development still has a much greater likelihood of not making it to market than of making it. If it can create an augmented IGF-1 effect in the injured brain that translates to improved patient outcome, however, NNZ2256 would be the single most important drug discovery that has occurred in the field of neurology.